Cargando…

The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer

• Ovarian cancer is the most lethal among gynecological cancers. • Carboplatin-based chemotherapy identifies as the main systemic treatment for ovarian cancer patients. • Almost one every three patients treated with carboplatin experiences hypersensitivity reactions. • Patients may experience breakt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vultaggio, Alessandra, Petrella, Maria Cristina, Tomao, Federica, Nencini, Francesca, Mecheri, Valentina, Marini, Andrea, Perlato, Margherita, Vivarelli, Emanuele, De Angelis, Claudia, Ferrarini, Ilaria, Pillozzi, Serena, Matucci, Andrea, Antonuzzo, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Reports and Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651898/ https://www.ncbi.nlm.nih.gov/pubmed/34926761 http://dx.doi.org/10.1016/j.gore.2021.100880

Ejemplares similares

Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review
por: Banini, Marco, et al.
Publicado: (2023)

How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
por: Bormioli, Susanna, et al.
Publicado: (2019)

Mechanisms of Drug Desensitization: Not Only Mast Cells
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

Baseline Eosinophil Count as a Potential Clinical Biomarker for Clinical Complexity in EGPA: A Real-Life Experience
por: Matucci, Andrea, et al.
Publicado: (2022)

EGPA Phenotyping: Not Only ANCA, but Also Eosinophils
por: Matucci, Andrea, et al.
Publicado: (2023)

Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors
por: Matucci, Andrea, et al.
Publicado: (2021)

Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE
por: R, Divya, et al.
Publicado: (2020)

Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?
por: Matucci, Andrea, et al.
Publicado: (2021)

Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?
por: Matucci, Andrea, et al.
Publicado: (2018)

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Pennington, Luke F., et al.
Publicado: (2016)

Serum free IgE guided dose reduction of omalizumab: a case report
por: Gon, Yasuhiro, et al.
Publicado: (2017)

A Case of Severe Asthma with Eosinophilic Otitis Media Successfully Treated with Anti-IgE Monoclonal Antibody Omalizumab
por: Okude, Azusa, et al.
Publicado: (2012)

Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

Desensitization Protocol to Carboplatin: A Technical Report
por: Nitipir, Cornelia, et al.
Publicado: (2022)

High Serum β-Lactams Specific/Total IgE Ratio Is Associated with Immediate Reactions to β-Lactams Antibiotics
por: Vultaggio, Alessandra, et al.
Publicado: (2015)

Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome
por: Alonso-Bello, Cesar Daniel, et al.
Publicado: (2019)

Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab
por: Kulka, M, et al.
Publicado: (2010)

Successful desensitization in a boy with severe cow’s milk allergy by a combination therapy using omalizumab and rush oral immunotherapy
por: Takahashi, Masaya, et al.
Publicado: (2015)

Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab
por: Saavedra, Michael C, et al.
Publicado: (2011)

Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect
por: Slevogt, Hortense, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich’s Syndrome
por: Matucci, Andrea, et al.
Publicado: (2018)

How the immune system responds to therapeutic biological agents
por: Vultaggio, Alessandra, et al.
Publicado: (2016)

Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
por: Kariyawasam, Harsha H, et al.
Publicado: (2020)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

Current and future applications of the anti-IgE antibody omalizumab
por: Incorvaia, Cristoforo, et al.
Publicado: (2008)

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma
por: D’Amato, Gennaro, et al.
Publicado: (2007)

The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review
por: Matucci, Andrea, et al.
Publicado: (2018)

Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis
por: Di Pietro, Linda, et al.
Publicado: (2023)

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells
por: Chan, Marcia A, et al.
Publicado: (2013)

Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review
por: D’Amato, Gennaro, et al.
Publicado: (2014)

272 Gender and Different Prevalence in Asthma Treatment With Anti-IGE (Omalizumab)
por: Patella, Vincenzo, et al.
Publicado: (2012)

Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab
por: Davies, Anna M., et al.
Publicado: (2017)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
por: Gambale, Elisabetta, et al.
Publicado: (2022)

IgG and IgE Autoantibodies to IgE Receptors in Chronic Spontaneous Urticaria and Their Role in the Response to Omalizumab
por: Maronese, Carlo Alberto, et al.
Publicado: (2023)

T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis
por: Pratesi, Sara, et al.
Publicado: (2019)

Omalizumab treatment in brittle asthma
por: Skiepko, Roman, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h96j3kum3j1nl59aqfu43sjq2s